These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

783 related articles for article (PubMed ID: 30577837)

  • 41. The efficacy and safety of immune-checkpoint inhibitors plus chemotherapy versus chemotherapy for non-small cell lung cancer: An updated systematic review and meta-analysis.
    Kang J; Zhang J; Tian Z; Xu Y; Li J; Li M
    PLoS One; 2024; 19(2):e0276318. PubMed ID: 38319920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Which Is More Suitable for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer, PD-L1 Inhibitors Versus PD-1 Inhibitors? A Systematic Review and Network Meta-Analysis.
    Liu W; Yu L; Feng Y; Huang S; Hua Y; Peng M; Ruan S; Zhang K
    Clin Respir J; 2024 Jul; 18(7):e13804. PubMed ID: 39073269
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
    Zhao Q; Xie R; Lin S; You X; Weng X
    Biomed Res Int; 2018; 2018():3820956. PubMed ID: 30345301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC).
    Zeng T; Qin Q; Bian Z; Li J
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4194-4201. PubMed ID: 31713435
    [No Abstract]   [Full Text] [Related]  

  • 46. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
    Brito ABC; Camandaroba MPG; de Lima VCC
    Thorac Cancer; 2021 Apr; 12(7):1058-1066. PubMed ID: 33586297
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
    Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
    Landre T; Des Guetz G; Chouahnia K; Taleb C; Vergnenègre A; Chouaïd C
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):441-448. PubMed ID: 31686247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
    Zhang J; Lv PY; Zhao X; Liu ML; Qiu LP; Yang ZZ; Sun SJ; Zhang GQ
    BMC Cancer; 2024 Aug; 24(1):967. PubMed ID: 39112947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis.
    Yang Y; Chen W; Dong L; Duan L; Gao P
    Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non-Small Cell Lung Cancer.
    Jiang T; Jin Q; Wang J; Wu F; Chen J; Chen G; Huang Y; Chen J; Cheng Y; Wang Q; Pan Y; Zhou J; Shi J; Xu X; Lin L; Zhang W; Zhang Y; Liu Y; Fang Y; Feng J; Wang Z; Hu S; Fang J; Shu Y; Cui J; Hu Y; Yao W; Li X; Lin X; Wang R; Wang Y; Shi W; Feng G; Ni J; Mao B; Ren D; Sun H; Zhang H; Chen L; Zhou C; Ren S
    Clin Cancer Res; 2023 Dec; 29(23):4830-4843. PubMed ID: 37449971
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Chen R; Hou X; Yang L; Zhao D
    Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis.
    Di Federico A; De Giglio A; Nuvola G; Deiana C; Conci N; Gelsomino F; Ardizzoni A
    Future Oncol; 2021 Nov; 17(32):4415-4424. PubMed ID: 34402681
    [No Abstract]   [Full Text] [Related]  

  • 57. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
    Lin LL; Lin GF; Luo Q; Chen XQ
    Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
    Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
    Wang C; Yu X; Wang W
    Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunotherapy or antiangiogenic therapy plus chemotherapy as first-line treatment of patients with PD-L1(-) advanced non-squamous non-small cell lung cancer in a Chinese cohort.
    Xia R; Li Y; Yang L; Huang M
    Cancer Med; 2023 Jul; 12(13):14282-14292. PubMed ID: 37212483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.